

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

HAYNES et al

Serial No. 09/775,805

Filed: February 5, 2001

For: HUMAN IMMUNODEFICIENCY VIRUS IMMUNOGENIC COMPOSITION

Confirmation No. 4002

Atty. Ref.: 1579-548

Group: 1648

Examiner: Stucker, J.

RECEIVED

APR 20 2005

OFFICE OF PETITIONS

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

April 20, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
 - ☐ a) The required Statement made in item 8 below; or
 - ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
 - ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
 - ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
 - ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
 - ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

HAYNES et al.
Serial No. 09/775,805
April 20, 2005

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: Mary J. Wilson
Mary J. Wilson
Reg. No. 32,955

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

1579-548

09/775,805

APPLICANT

HAYNES et al

(Use several sheets if necessary)

FILING DATE

GROUP

February 5, 2001

1648

RECEIVED

APR 20 2005

OFFICE OF PETITIONS**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	20010036461	11/2001	Haynes et al			
	20040132010	7/2004	Haynes et al			
	20020086283	7/2002	Haynes et al			
	20040039172	2/2004	Haynes et al			
	5,516,632	5/1996	Palker et al			
	20040197344	10/2004	Haynes et al			
	2004086506	5/2004	Haynes et al			
	2004001851	1/2004	Haynes et al			
	20030147888	8/2003	Haynes et al			

FOREIGN PATENT DOCUMENTS

							TRANSLATION	
DOCUMENT		DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
	WO 2004/075850	9/2004	WIPO					
	WO 2005/016952	2/2005	WIPO					
	WO 2004/009785	1/2004	WIPO					
	WO 03/046137	6/2003	WIPO					
	WO 2005/028625	3/2005	WIPO					

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	U.S. Provisional Application No. 60/503,460 filed September 17, 2003 and U.S. Provisional Application No. 60/604,722 filed August 27, 2004 (see attached copy of WO 2005/028625)
	U.S. Patent Application No. 10/518,523 filed December 21, 2004 (U.S. National Phase of WO 2004/009785 see above)
	U.S. Patent Application No. 10/973,977 filed October 27, 2004
	U.S. Patent Application No. 10/973,475 filed October 27, 2004
	U.S. Provisional Application No. 60/625,720 filed November 8, 2004
	DATABASE Geneseq 'Online!, 12 May 1999, "T cell epitope/MHC ligand SEQ ID NO:226.", retrieved from EBI accession no. GSN:AAY10296, Database accession no. AAY10296 & WO 99/02183 A (Simard John J L; CTL Immunotherapies Corp (CA); Kuendig Thomas M (CH)) 21 January 1999- XP002303500
	Oscherwitz et al, "A V3 loop haptenic peptide sequence, when tandemly repeated, enhances immunogenicity by facilitating helper T-cell responses to a covalently linked carrier protein", Vaccine 17:2392-2399 (1999)
	Borbe et al, "Structural and Immunological Reactivity of the Principal Neutralizing Determinant V3 of Glycoprotein gp120 of HIV-1", Journal of Peptide Science 1:109-123 (1995)
	Winchell et al, "Mucosal Immune Response to an HIV C4/V3 Peptide Following Nasal or Intestinal Immunization of Rabbits", AIDS Research and Human Retroviruses 13(10):881-889 (1997)
	Kelleher et al, "Safety and Immunogenicity of UBI HIV-1MN Octameric V3 Peptide Vaccine Administered by Subcutaneous Injection", AIDS Research and Human Retroviruses 13(1):29-32 (1997)
*Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Affy. Docket No.

Serial No.

1579-548

09/775,805 RECEIVED

Applicant

HAYNES et al

APR 20 2005

Filing Date

TC/A.U.

February 5, 2001

OFFICE OF PETITIONS

U.S. PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	<p>DATABASE Geneseq 'Online!, 14 September 1999, "HIV-derived lipopeptide epitope GAG253 for mixed micelles.", retrieved from EBI accession no. GSN:AAY26615 Database accession no. AAY26615 & WO 99/27954 A (Gras Masse Helene; Guillet Jean Gerard (FR); Inst. Nat. Sante Rech. Med) 10 June 1999 - XP002303503</p>
	<p>DATABASE Geneseq 'Online!, 22 February 2000, "HLA-A2-binding HIV-1 GP41 CTL epitope #250, retrieved from EBI accession no. GSN:AAY66448 Database accession no. AAY66448 & WO 99/49893 A (Univ Boston) 7 October 1999 - XP002303504</p>
	<p>Gao et al, "Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID networks for HIV isolation and characterization", Journal of Virology, The American Society for Microbiology 70(3):1651-1667 (1996)</p>
	<p>DATABASE Geneseq 'Online!, 12 November 1990, "Peptide component of AIDS vaccine.", retrieved from EBI accession no. GSN:AAP82469 Database accession no. AAP82469 & EP 0 273 716 A (US Health) 6 July 1988 - XP002303505</p>
	<p>DATABASE USPTO Proteins 'Online!, 7 October 1996, "Sequence 17 from patent US 5519114.", retrieved from EBI accession no. USPOP:AAB13195 Database accession no. AAB13195 & US 5 519 114 A (Johnson Howard M et al) 21 May 1996 - XP002303506</p>
	<p>DATABASE EPO Proteins 'Online!, 26 April 1994, "antigen which binds to antibodies with an affinity for HIV-1 p24", retrieved from EBI accession no. EPOP:A18855 Database accession no. A18855 & WO 91/13360 A (Replico Medical AB) 5 September 1991 - XP002303507</p>
	<p>DATABASE EPO Proteins 'Online!, 26 April 1994, "antigen which binds to antibodies with an affinity for HIV-1 p24", retrieved from EBI accession no. EPOP:A18953 Database accession no. A18953 & WO 91/13360 A (Replico Medical AB) 5 September 1991 - XP002303508</p>
	<p>DATABASE EPO Proteins 'Online!, 14 July 1993, "Human immunodeficiency virus gag protein", retrieved from EBI accession no. EPOP:A04294 Database accession no. A04294 & WO 86/02383 A (Centre Nat. Rech. Scient. Pasteur Institut (FR)) 24 April 1986 - XP002303509</p>
	<p>DATABASE EPO Proteins 'Online!, 23 August 1995, "Cytotoxic T lymphocyte epitope 19 derived from gag p17 (MA) protein.", retrieved from EBI accession no. GSN:AAR68762 Database accession no. AAR68762 & WO 94/28871 A (Endocon Inc) 22 December 1994 - XP002303510</p>

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.



P.B. 5818 - Patentlaan 2
2280 HV Rijswijk (ZH)
☎ +31 70 340 2040
TX 31651 epo nl
FAX +31 70 340 3016

Europäisches
Patentamt

Zweigstelle
in Den Haag
Recherchen-
abteilung


European
Patent Office

Branch at
The Hague
Search
division

Office européen
des brevets

Département à
La Haye
Division de la
recherche

Woods, Geoffrey Corlett
J.A. KEMP & CO.
Gray's Inn
14 South Square
London WC1R 5JJ
GRANDE BRETAGNE



RECEIVED
APR 20 2005
OFFICE OF PETITIONS

Datum/Date

22.11.04

Zeichen/Ref./Réf. N.86275PJC	Anmeldung Nr./Application No./Demande n°/Patent Nr./Patent No./Brevet n°. 01905398.2
Anmelder/Applicant/Demandeur/Patentinhaber/Proprietor/Titulaire Beth Israel Deaconess Medical Center, et al	

COMMUNICATION

The European Patent Office herewith transmits

- ☐ the European search report
- ☐ the declaration under Rule 45 EPC
- ☒ the partial European search report under Rule 45 EPC
- ☐ the supplementary European search report concerning the international application under Article 157(2) EPC relating to the above-mentioned European patent application. Copies of the documents cited in the search report are enclosed.

The following specifications given by the applicant have been approved by the Search Division:

- ☐ Abstract ☐ Title ☐ Figure
- ☐ The abstract was modified by the Search Division and the definitive text is attached to this communication.
- ☐ The following figure will be published with the abstract, since the Search Division considers that it better characterises the invention than the one indicated by the applicant.

Figure:

- ☒ Additional copy(copies) of the documents cited in the European search report.

REFUND OF THE SEARCH FEE

If applicable under Article 10 Rules relating to fees, a separate communication from the Receiving Section on the refund of the search fee will be sent later.

EPO Form 1507 02.93





CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

- ☐ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- ☒ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
1-8 partially, relating to inventions 1,12,13,14,15,26,27,28,29
- ☐ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
mouse A-Th/A-CTL in Table 3

2. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
mouse B-Th/B-CTL in Table 3

3. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
mouse C-Th/C-CTL in Table 3

4. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
mouse D-Th/D-CTL in Table 3

5. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
macaque Th1/CTL/SIV Gag in Table 3

6. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
macaque Th2/CTL/SIV Pol in Table 3

7. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
macaque Th3/CTL/HIV-1 Env in Table 3

8. claims: 1-8 partially



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
macaque Th2/CTL/SIV Gag/p11c/I-Y in Table 3

9. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
macaque Th3/CTL/SIV Gag/p11c/I-A in Table 3

10. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
macaque Th4/CTL/SIV Gag/p11c/I-D in Table 3

11. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
macaque Th5/CTL/SIV Gag/p11c/I-K in Table 3

12. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
human A-Th/A-CTL in Table 3 (Cont'd)

13. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
human B-Th/B-CTL in Table 3 (Cont'd)

14. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
human C-Th/C-CTL in Table 3 (Cont'd)

15. claims: 1-8 partially



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
human D-Th/D-CTL in Table 3 (Cont'd)

16. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
human A-Th/E-CTL in Table 3 (Cont'd)

17. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
human B-Th/F-CTL in Table 3 (Cont'd)

18. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
human C-Th/G-CTL in Table 3 (Cont'd)

19. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
human D-Th/H-CTL in Table 3 (Cont'd)

20. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
E-Th/I-CTL in Table 3 (Cont'd)

21. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
human B-Th/E-CTL in Table 3 (Cont'd)

22. claims: 1-8 partially



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
human C-Th/J-CTL in Table 3 (Cont'd)

23. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
human A-Th/K-CTL in Table 3 (Cont'd)

24. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
human D-Th/L-CTL in Table 3 (Cont'd)

25. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
human E-Th/M-CTL in Table 3 (Cont'd)

26. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
human A*-Th/J-CTL in Table 3 (Cont'd)

27. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
human A*-Th/K-CTL in Table 3 (Cont'd)

28. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
human A*-Th/L-CTL in Table 3 (Cont'd)

29. claims: 1-8 partially



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
human A*-Th/M-CTL in Table 3 (Cont'd)

30. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
MVA-1 in Table 4

31. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
MVA-2 in Table 4

32. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
MVA-3 in Table 4

33. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
MVA-4 in Table 4

34. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
MVA-5 in Table 4

35. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
MVA-6 in Table 4

36. claims: 1-8 partially



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
MVA-7 in Table 4

37. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
MVA-8 in Table 4

38. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
MVA-9 in Table 4

39. claims: 1-8 partially

vaccine, polypeptide, DNA sequence, composition
corresponding to the peptide named
MVA-10 in Table 4



European Patent
Office

SUPPLEMENTARY

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 01 90 5398 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
D,X	BARTLETT J A ET AL: "SAFETY AND IMMUNOGENICITY OF AN HLA-BASED HIV ENVELOPE POLYVALENT SYNTHETIC PEPTIDE IMMUNOGEN" AIDS, LONDON, GB, vol. 12, no. 11, 30 July 1998 (1998-07-30), pages 1291-1300, XP008008599 ISSN: 0269-9370 * the whole document *	1-8	A61B1/00 C07K14/16
Y	US 5 976 551 A (MOTTEZ ESTELLE ET AL) 2 November 1999 (1999-11-02) see peptide HIV 1 GAG 219-233, SEQ ID N°30 * column 11; table 6 *	1-8	
Y	WO 96/41189 A (US HEALTH ; SHEARER GENE M (US); BERZOFKY JAY A (US); CLERICI MARI) 19 December 1996 (1996-12-19) see peptide T1 from HIV-1 GP 160, (Env 428-443) * page 13; table 1 *	1-8	
-/--			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C12N C07K

The supplementary search report has been based on the last set of claims valid and available at the start of the search.

INCOMPLETE SEARCH

The Search Division considers that the present application, or some or all of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for the following claims:

Claims searched completely :

Claims searched incompletely :

Claims not searched :

Reason for the limitation of the search:

see sheet C

Place of search

Munich

Date of completion of the search

8 November 2004

Examiner

Loubradou-Bourges, N

CATEGORY OF CITED DOCUMENTS

X : particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A : technological background
O : non-written disclosure
P : intermediate document

T : theory or principle underlying the invention
E : earlier patent document, but published on, or after the filing date
D : document cited in the application
L : document cited for other reasons

& : member of the same patent family, corresponding document



DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	HALE P M ET AL: "T CELL MULTIDETERMINANT REGIONS IN THE HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE: TOWARD OVERCOMING THE PROBLEM OF MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION" INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 1, no. 4, 1 September 1989 (1989-09-01), pages 409-415, XP000605987 ISSN: 0953-8178 * the whole document *	1-8	
A	LOKTEV V B ET AL: "Design of immunogens as components of a new generation of molecular vaccines" JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 44, no. 1, 26 January 1996 (1996-01-26), pages 129-137, XP004036858 ISSN: 0168-1656 * the whole document *	1-8	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	DATABASE Geneseq 'Online! 12 May 1999 (1999-05-12), "T cell epitope/MHC ligand SEQ ID NO:226." XP002303500 retrieved from EBI accession no. GSN:AAY10296 Database accession no. AAY10296 * the whole document * & WO 99/02183 A (SIMARD JOHN J L ; CTL IMMUNOTHERAPIES CORP (CA); KUENDIG THOMAS M (CH)) 21 January 1999 (1999-01-21) ----- -/--	1-8	



DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	DATABASE Geneseq 'Online! 15 October 1997 (1997-10-15), "HIV epitope env T1 amino acid residues 428-443 of gp120." XP002303501 retrieved from EBI accession no. GSN:AAW10345 Database accession no. AAW10345 * the whole document * & WO 96/41189 A (US HEALTH ; SHEARER GENE M (US); BERZOFKY JAY A (US); CLERICI MARIO () 19 December 1996 (1996-12-19) * claim 15 *	1-8	
Y	DATABASE Geneseq 'Online! 16 January 1998 (1998-01-16), "HIV gag p24 protein epitope GTH1." XP002303502 retrieved from EBI accession no. GSN:AAW19019 Database accession no. AAW19019 * the whole document * & WO 97/14436 A (UNIV DUKE) 24 April 1997 (1997-04-24)	1-8	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	DATABASE Geneseq 'Online! 14 September 1999 (1999-09-14), "HIV-derived lipopeptide epitope GAG253 for mixed micelles." XP002303503 retrieved from EBI accession no. GSN:AAY26615 Database accession no. AAY26615 * the whole document * & WO 99/27954 A (GRAS MASSE HELENE ; GUILLET JEAN GERARD (FR); INST NAT SANTE RECH MED) 10 June 1999 (1999-06-10) ----- -/--	1-8	



DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	DATABASE Geneseq 'Online! 22 February 2000 (2000-02-22), "HLA-A2-binding HIV-1 GP41 CTL epitope #250." XP002303504 retrieved from EBI accession no. GSN:AAY66448 Database accession no. AAY66448 * the whole document * & WO 99/49893 A (UNIV BOSTON) 7 October 1999 (1999-10-07)	1-8	
Y	GAO F ET AL: "Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID networks for HIV isolation and characterization" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 70, no. 3, March 1996 (1996-03), pages 1651-1667, XP002123321 ISSN: 0022-538X see sequence Q70021	1-8	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	DATABASE Geneseq 'Online! 12 November 1990 (1990-11-12), "Peptide component of AIDS vaccine." XP002303505 retrieved from EBI accession no. GSN:AAP82469 Database accession no. AAP82469 * the whole document * & EP 0 273 716 A (US HEALTH) 6 July 1988 (1988-07-06)	1-8	

-/--



DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	DATABASE USPTO Proteins 'Online! 7 October 1996 (1996-10-07), "Sequence 17 from patent US 5519114." XP002303506 retrieved from EBI accession no. USPOP:AAB13195 Database accession no. AAB13195 * the whole document * & US 5 519 114 A (JOHNSON HOWARD M ET AL) 21 May 1996 (1996-05-21) -----	1-8	
Y	DATABASE EPO Proteins 'Online! 26 April 1994 (1994-04-26), "antigen which binds to antibodies with an affinity for HIV-1 p24" XP002303507 retrieved from EBI accession no. EPOP:A18855 Database accession no. A18855 * the whole document * & WO 91/13360 A (REPLICO MEDICAL AB) 5 September 1991 (1991-09-05) -----	1-8	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	DATABASE EPO Proteins 'Online! 26 April 1994 (1994-04-26), "antigen which binds to antibodies with an affinity for HIV-1 p24" XP002303508 retrieved from EBI accession no. EPOP:A18953 Database accession no. A18953 * the whole document * & WO 91/13360 A (REPLICO MEDICAL AB) 5 September 1991 (1991-09-05) ----- -/--	1-8	



DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	DATABASE EPO Proteins 'Online! 14 July 1993 (1993-07-14), "Human immunodeficiency virus gag protein" XP002303509 retrieved from EBI accession no. EPOP:A04294 Database accession no. A04294 * the whole document * & WO 86/02383 A (CENTRE NAT RECH SCIENT ; PASTEUR INSTITUT (FR)) 24 April 1986 (1986-04-24) -----	1-8	
Y	DATABASE Geneseq 'Online! 23 August 1995 (1995-08-23), "Cytotoxic T lymphocyte epitope 19 derived from gag p17 (MA) protein." XP002303510 retrieved from EBI accession no. GSN:AAR68762 Database accession no. AAR68762 * the whole document * & WO 94/28871 A (ENDOCON INC) 22 December 1994 (1994-12-22) -----	1-8	TECHNICAL FIELDS SEARCHED (Int.Cl.7)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 90 5398

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

08-11-2004

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 5976551	A	02-11-1999	US	6153408 A	28-11-2000
			US	6011146 A	04-01-2000
WO 9641189	A	19-12-1996	AU	6111896 A	30-12-1996
			WO	9641189 A1	19-12-1996
WO 9902183	A	21-01-1999	CA	2209815 A1	10-01-1999
			AU	739189 B2	04-10-2001
			AU	8568998 A	08-02-1999
			CA	2295964 A1	21-01-1999
			EP	1003548 A1	31-05-2000
			JP	2001509490 T	24-07-2001
			NZ	502168 A	28-08-2002
			WO	9902183 A2	21-01-1999
			US	2002007173 A1	17-01-2002
WO 9641189	A	19-12-1996	AU	6111896 A	30-12-1996
			WO	9641189 A1	19-12-1996
WO 9714436	A	24-04-1997	US	5993819 A	30-11-1999
			AU	7465696 A	07-05-1997
			CA	2235168 A1	24-04-1997
			EP	0868196 A1	07-10-1998
			JP	11515006 T	21-12-1999
			NO	961680 A	29-10-1996
			WO	9714436 A1	24-04-1997
WO 9927954	A	10-06-1999	FR	2771640 A1	04-06-1999
			AU	1440099 A	16-06-1999
			CA	2312043 A1	10-06-1999
			EP	1035866 A2	20-09-2000
			WO	9927954 A2	10-06-1999
			JP	2002506001 T	26-02-2002
WO 9949893	A	07-10-1999	AU	3375599 A	18-10-1999
			WO	9949893 A1	07-10-1999
			US	2003103964 A1	05-06-2003
EP 0273716	A	06-07-1988	AT	92934 T	15-08-1993
			AU	592258 B2	04-01-1990
			AU	1365788 A	27-07-1988
			DE	3787002 D1	16-09-1993
			DE	3787002 T2	25-11-1993
			EP	0273716 A2	06-07-1988
			IL	84980 A	10-06-1993
			JP	7062031 B	05-07-1995

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 90 5398

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

08-11-2004

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0273716	A		JP 63503227 T	24-11-1988
			WO 8805051 A1	14-07-1988
			US 5939074 A	17-08-1999
			US 5081226 A	14-01-1992
US 5519114	A	21-05-1996	AU 1085595 A	22-05-1995
			CA 2175255 A1	04-05-1995
			EP 0730650 A1	11-09-1996
			JP 9505282 T	27-05-1997
			WO 9511975 A2	04-05-1995
			US 5968514 A	19-10-1999
WO 9113360	A	05-09-1991	SE 468168 B	16-11-1992
			AU 7444891 A	18-09-1991
			SE 9000595 A	21-08-1991
			WO 9113360 A1	05-09-1991
WO 8602383	A	24-04-1986	FR 2571968 A1	25-04-1986
			AT 64601 T	15-07-1991
			AT 92502 T	15-08-1993
			AT 86636 T	15-03-1993
			AT 250083 T	15-10-2003
			AU 603543 B2	22-11-1990
			AU 5061785 A	02-05-1986
			DE 3583293 D1	25-07-1991
			DE 3587181 D1	15-04-1993
			DE 3587181 T2	24-06-1993
			DE 3587512 D1	09-09-1993
			DE 3587512 T2	02-12-1993
			DE 3588248 D1	23-10-2003
			DK 35593 A	26-03-1993
			DK 284986 A	14-08-1986
			WO 8602383 A1	24-04-1986
			EP 1231271 A2	14-08-2002
			EP 1279678 A1	29-01-2003
			EP 0201540 A1	20-11-1986
			EP 0387914 A1	19-09-1990
			EP 0387915 A1	19-09-1990
			EP 0462627 A1	27-12-1991
			ES 8705522 A1	16-07-1987
			ES 8801318 A1	01-03-1988
			ES 8801319 A1	01-03-1988
			GR 852522 A1	17-02-1986
			IE 64006 B1	28-06-1995
			JP 2971034 B2	02-11-1999
			JP 9132594 A	20-05-1997

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 90 5398

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

08-11-2004

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8602383 A		JP 2761376 B2	04-06-1998
		JP 9118689 A	06-05-1997
		JP 2777115 B2	16-07-1998
		JP 9178751 A	11-07-1997
		JP 2752329 B2	18-05-1998
		JP 7309779 A	28-11-1995
		JP 2609448 B2	14-05-1997
		JP 62500592 T	12-03-1987
		KR 9300189 B1	11-01-1993
		NZ 230372 A	25-02-1994
		PT 81338 A , B	01-11-1985
		US 5705612 A	06-01-1998
		US 5610035 A	11-03-1997
		US 6261564 B1	17-07-2001
		US 6706268 B1	16-03-2004
		US 5980900 A	09-11-1999
		ZA 8508034 A	25-06-1986
		US 6555112 B1	29-04-2003
		US 5843638 A	01-12-1998
		US 6440657 B1	27-08-2002
		AT 51876 T	15-04-1990
WO 9428871 A	22-12-1994	AU 7101294 A	03-01-1995
		WO 9428871 A1	22-12-1994



Claim(s) searched incompletely:
2-8

Reason for the limitation of the search:

Present claims 2-8 relate to an extremely large number of possible compounds. Support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds mentioned in Table 3 and 4.